Dr. Ranee Mehra, MD
Claim this profileUniversity of Maryland/Greenebaum Cancer Center
Expert in Thyroid Cancer
Expert in Squamous Cell Carcinoma
29 reported clinical trials
56 drugs studied
Area of expertise
1Thyroid Cancer
Global LeaderStage IV
Stage III
metastatic
2Squamous Cell Carcinoma
Global LeaderStage IV
Stage III
metastatic
Affiliated Hospitals
Clinical Trials Ranee Mehra, MD is currently running
ADT + Pembrolizumab
for Salivary Gland Cancer
A Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not amenable to surgery or radiation.
Recruiting1 award Phase 221 criteria
Cetuximab + Pembrolizumab
for Head and Neck Cancer
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) and/or that has spread from where it first started (primary site) to other places in the body (metastatic). Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of tumor cells. This may help keep tumor cells from growing. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving cetuximab and pembrolizumab together may be more effective at treating patients with recurrent and/or metastatic HNSCC than pembrolizumab alone.
Recruiting2 awards Phase 316 criteria
More about Ranee Mehra, MD
Clinical Trial Related6 years of experience running clinical trials · Led 29 trials as a Principal Investigator · 11 Active Clinical TrialsTreatments Ranee Mehra, MD has experience with
- Pembrolizumab
- Cisplatin
- Binimetinib
- Cetuximab
- Ipatasertib
- Palbociclib
Breakdown of trials Ranee Mehra, MD has run
Thyroid Cancer
Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma
Head and Neck Cancers
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ranee Mehra, MD specialize in?
Ranee Mehra, MD focuses on Thyroid Cancer and Squamous Cell Carcinoma. In particular, much of their work with Thyroid Cancer has involved Stage IV patients, or patients who are Stage III.
Is Ranee Mehra, MD currently recruiting for clinical trials?
Yes, Ranee Mehra, MD is currently recruiting for 11 clinical trials in Baltimore Maryland. If you're interested in participating, you should apply.
Are there any treatments that Ranee Mehra, MD has studied deeply?
Yes, Ranee Mehra, MD has studied treatments such as Pembrolizumab, Cisplatin, Binimetinib.
What is the best way to schedule an appointment with Ranee Mehra, MD?
Apply for one of the trials that Ranee Mehra, MD is conducting.
What is the office address of Ranee Mehra, MD?
The office of Ranee Mehra, MD is located at: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland 21201 United States. This is the address for their practice at the University of Maryland/Greenebaum Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.